Table 6.
Types | Result in ST Cross |
Result in HB Cross |
Range of Treated Doses and Remarks | Ref. |
---|---|---|---|---|
Carbon nanotubes | - | nd | 64–1000 µg/mL, all doses lack genotoxicity | [110] |
Carbon nanotubes | - | - | 50–250 µg/mL, lack genotoxicity at 50, 100, and 200 µg/mL and inconclusive at 150 and 250 µg/mL in both ST and HB cross | [111] |
Cobalt nanoparticles | - | nd | 0.1–10 mM, lack genotoxicity up to 5 mM and inconclusive at 10 mM | [112] |
Copper oxide nanoparticles (CuONPs) | + | nd | 0.24–0.95 mg/mL, lack genotoxicity at 0.24 mg/mL and inconclusive at 0.48 mg/mL but positive at 0.95 mg/mL in ST cross | [105] |
Gold nanoparticles | - | - | 20–30 µg/mL, all of doses inconclusive in ST cross, whereby all of concentrations lack genotoxicity in HB cross | [113] |
Iron oxide nanoparticle (<50 nm) |
+ | nd | 1–10 mM, inconclusive at 2 and 5 mM, positive at 1 and 10 mM | [114] |
Iron oxide nanoparticle (<100 nm) |
- | nd | 1–10 mM, inconclusive at 1 mM and lack genotoxicity 2–10 mM | [114] |
Iron nanoparticles | - | nd | 0.1–10 mM, all concentrations lack genotoxicity | [115] |
Nickel oxide nanoparticles | + | + | 1.31–21 mg/mL, all of doses positive in ST cross but lack genotoxicity up to 10.50 mg/mL and positive at 21 mg/mL in HB cross | [108] |
Titanium dioxide nanocrystal (A3.4 TiO2 NCs) | + | + | 1.5625–12.5 mM, lack genotoxicity up to 6.25 and positive at 12.5 mM in ST cross; moreover, at 12.5 mM lack genotoxicity, 6.25 mM inconclusive, and positive at 1.5625 and 3.125 mM in HB cross | [112] |
Titanium dioxide nanocrystal (A6.2 TiO2 NCs) | - | - | 1.5625–12.5 mM, lack genotoxicity up to 12.5 and inconclusive at 1.5625 in both ST and HB cross | [112] |
Titanium dioxide nanoparticles | - | nd | 0.08–1.60 mg/mL, all concentrations lack genotoxicity | [106] |
Zinc oxide nanoparticles | + | - | 0.075–1.2 mg/mL, lack genotoxicity up to 0.15 mg/mL and positive at 0.3–1.2 mg/mL in ST cross; however, all of doses lack genotoxicity in HB cross | [116] |
nd—not determined, (-)—negative, and (+)—positive.